{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:04:56Z","timestamp":1760058296339,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Orofacial granulomatosis is a rare but often disabling condition potentially associated with inflammatory bowel disease (IBD). Pathogenesis is not well understood, and no disease-specific approved treatment exists to date. Case Presentation: A 26-year-old woman with pan-enteric Crohn\u2019s disease developed buccal swelling and deep oral ulcers histologically confirmed as associated orofacial granulomatosis. Multiple therapies were attempted during her life, including systemic steroids and immunomodulator drugs as Thalidomide, Adalimumab, and Ustekinumab in combination with topical steroid injections and Cyclosporin application, with no or minimal benefit. Only Infliximab showed good efficacy, but it was suspended due to side effects. Following secondary loss of response to Ustekinumab, compassionate treatment with Upadacitinib, a recently developed oral Jak-1 selective inhibitor, resulted in the complete resolution of the oral ulcers. Moreover, after the 12-week induction phase and the transition to 30 mg\/daily maintenance dosage, the oral disease remained controlled. Due to the clinical recurrence of Crohn\u2019s disease, Vedolizumab was added as associated treatment, resulting in complete clinical benefit after six months of follow-up. Conclusions: This is a unique case of orofacial granulomatosis associated with pan-enteric Crohn\u2019s disease successfully treated with Upadacitinib. More data are needed to explore its potential benefits in this clinical condition.<\/jats:p>","DOI":"10.3390\/reports8020037","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T13:48:20Z","timestamp":1742824100000},"page":"37","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Upadacitinib and Vedolizumab Combination for Refractory Orofacial Granulomatosis Associated with Panenteric Crohn\u2019s Disease: A Case Report"],"prefix":"10.3390","volume":"8","author":[{"given":"Michele","family":"Campigotto","sequence":"first","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy Unit, Ca\u2019Foncello Hospital, ULSS2 Marca Trevigiana, 31100 Treviso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Priotto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia Francesca","family":"Tonello","sequence":"additional","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy Unit, Cattinara University Hospital, 34127 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-1269","authenticated-orcid":false,"given":"Fabio","family":"Monica","sequence":"additional","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy Unit, Cattinara University Hospital, 34127 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-7011","authenticated-orcid":false,"given":"Saveria Lory","family":"Croc\u00e8","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy"},{"name":"Liver Clinic, Maggiore University Hospital, 34127 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/flgastro-2023-102619","article-title":"Oral manifestations of inflammatory bowel disease: A guide to examination","volume":"15","author":"Joshi","year":"2024","journal-title":"Front. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/ecco-jcc\/jjab158","article-title":"Orofacial Granulomatosis Associated with Crohn\u2019s Disease: A Multicentre Case Series","volume":"16","author":"Phillips","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1601-0825.2012.01918.x","article-title":"Biologics in oral medicine: Oral Crohn\u2019s disease and orofacial granulomatosis","volume":"18","author":"Scully","year":"2012","journal-title":"Oral Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/ecco-jcc\/jjae083","article-title":"Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn\u2019s Disease","volume":"18","author":"Ghosh","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn\u2019s Disease","volume":"69","author":"Miyatani","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109545","DOI":"10.1016\/j.intimp.2022.109545","article-title":"Combination therapy in inflammatory bowel disease: Current evidence and perspectives","volume":"114","author":"Dai","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s13555-024-01117-z","article-title":"Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib","volume":"14","author":"Benjelloun","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2023.03.024","article-title":"Use of Janus kinase inhibitors for granulomatous dermatoses: A systematic review","volume":"89","author":"Sood","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1093\/ibd\/izaa123","article-title":"Using Ustekinumab to Treat Crohn\u2019s Disease\u2013Related Orofacial Granulomatosis: Two Birds, One Stone","volume":"26","author":"Gilmore","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn\u2019s disease: A UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Front. Gastroenterol."},{"key":"ref_13","first-page":"060","article-title":"Upadacitinib in Patients With Difficult-to-Treat Crohn\u2019s Disease","volume":"6","author":"Bezzio","year":"2024","journal-title":"Crohn\u2019s Colitis 360"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: Systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2022","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"otad053","DOI":"10.1093\/crocol\/otad053","article-title":"Vedolizumab in Mild-to-Moderate Crohn\u2019s Disease Patients Na\u00efve to Biological Therapy: A Multicentric Observational Study","volume":"5","author":"Dotti","year":"2023","journal-title":"Crohn\u2019s Colitis 360"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","article-title":"Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig. Dis. Sci."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/37\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:58:40Z","timestamp":1760029120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["reports8020037"],"URL":"https:\/\/doi.org\/10.3390\/reports8020037","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2025,3,23]]}}}